BioCardia 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- BioCardia said it had answered all remaining questions from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to the agency’s satisfaction and was proceeding toward a Shonin submission for CardiAMP cell therapy with its designated marketing authorization holder.
- The company said four U.S. clinical sites were actively recruiting for the CardiAMP Heart Failure 2 trial, with seven additional centers being onboarded, and management was aware of no safety issues.
- The FDA accepted as final, without changes, the minutes BioCardia provided following its May 2026 meeting, and accepted the company’s supplemental de novo pre-submission for the Helix TransendoCardial Delivery System.
- Net cash used in operations was approximately $1.7 million in Q3 2026, compared with $1.7 million in Q3 2025; year-to-date cash used was $5.1 million, compared with $4.9 million in the same period in 2025.
- BioCardia ended the quarter with $2.2 million in cash and cash equivalents, providing runway into 2027.
- Q3 2026 R&D expenses were $1.2 million, compared with $0.9 million in Q3 2025; year-to-date R&D expenses were $3.4 million, compared with $3.8 million, primarily due to completion of the CardiAMP Heart Failure trial.
- Q3 2026 SG&A expenses were $0.6 million, compared with $0.55 million in Q3 2025; year-to-date SG&A expenses were $2.4 million, consistent with Q3 year-to-date 2025.
- Net loss was $1.8 million in Q3 2026, compared with $1.5 million in Q3 2025; year-to-date net loss was $5.7 million, compared with $6.2 million, primarily due to lower R&D expenses.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and welcome to the BioCardia Q3 2026 financial results and corporate update conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchscreen or keypad. To withdraw your question, please press star then two. Participants of this call are advised that the audio of this conference call is being broadcast live over the internet and is also being recorded for playback purposes. A webcast replay of the call will be available approximately one hour after the end of the call. I would now like to turn the call over to Miranda Peto of BioCardia Investor Relations. Please go ahead, Miranda. Thank you.
Good afternoon, and thank you for participating in today's conference call. Joining me from BioCardia's leadership team are Peter Altman, President and Chief Executive Officer, and David McClung, the company's Chief Financial Officer. During this call, management will be making forward-looking statements, including statements that address BioCardia's expectations for future performance and operational results, references to management's intentions, beliefs, projections, outlook, analyses, and current expectations. Such factors include, among others, the inherent uncertainties associated with developing new products, technologies, and obtaining regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors and cautionary statements described in BioCardia's report on Form 10-K filed with the SEC on March 24, 2026, and in our subsequently filed quarterly reports on Form 10-Q.
The content of this call contains time-sensitive information that is accurate only as of today, November 12, 2026. Except as required by law, the company disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call. It is now my pleasure to turn the call over to Dr. Peter Altman, BioCardia's President and CEO.
Peter, please go ahead. Thank you, Miranda, and good afternoon to everyone on the call.
The highlights of this second quarter have been the continued progress on the approval of CardiAMP Cell Therapy for the treatment of heart failure in Japan and the approval of our Helix Transendocardial Delivery Catheter System in the United States. I would like to focus a little time on each of these regulatory initiatives to detail where we are at, the risks, and our anticipated successful outcomes. Our efforts to seek approval in Japan for our CardiAMP Cell Therapy for the treatment of ischemic heart failure follow Japan's leadership supporting these therapies, as they have recognized the potential for meaningful impact to treat heart failure. They have recently approved and reimbursed a cell therapy in Japan for patients with heart failure.
Our CardiAMP Cell Therapy may have advantages over what has been approved in that it is autologous and requires no immunosuppression. Delivering a patient's own cells resonates with Japanese culture that has historically avoided the transplantation of organs. Further, our CardiAMP Cell Therapy procedure is performed using minimally invasive catheter delivery without need for opening the patient's chest surgically to deliver the cells. We expect to be able to discharge the patient soon after the procedure on the same day. The patient need is great, and we look forward to real-world assessment of the CardiAMP Cell Therapy for these patients in Japan. In our last quarter, we shared that we had remaining questions to address before the submission of CardiAMP Cell Therapy for regulatory approval in Japan.
We have answered all of these questions to Japan's Pharmaceuticals and Medical Devices Agency satisfaction, and we are proceeding to Shonin submission with our designated marketing authorization holder. Our designated marketing authorization holder will prepare and submit the Shonin application and act as the local regulatory representative to enable BioCardia sales of CardiAMP Cell Therapy in Japan. Our work with them is also supported by additional preparatory consultancies that we have engaged. The timing of this is fluid, but it looks like most tasks will be completed in the coming months. A primary risk of this timeline is if our product documentation does not meet a requisite standard and we need to repeat testing of some sort. No deficiencies have yet been identified by BioCardia. However, as we work with our designated marketing authorization holder, we may identify areas where they may request additional work.
We have been getting ready for some time preparing for this. Our team recently completed a recertification audit to the international standard that sets requirements for a quality management system specifically tailored for our industry. Our team has also taken steps to revalidate our product sterilization process with an eye towards Japanese regulations. The expected initial clinical indication in Japan will be for approximately 20,000 patients, with approval expected 12 months after we complete our Shonin submission. During this period, we would expect to be training physicians and finalizing the details of the post-marketing study and its logistics so that we are ready to begin at all centers as soon as approval by the Ministry of Health, Labour, and Welfare, and subsequent reimbursement has been established.
Although our initial approval is only expected to be for 20,000 patients in Japan, we note that there are approximately 300,000 patients in Japan with ischemic heart failure today. Japan's world-class interventional cardiologists perform 250,000 cardiac catheter interventions per year. Our enhancing both physician and patient success after approval in the post-marketing study, where there will be reimbursement, is likely to result in a significant business that has a very positive impact on patients and society in Japan. Japan's approval of CardiAMP cell therapy, which includes the Helix biotherapeutic delivery catheter, may also help other developers of cardiac biologic therapy in Japan. In the U.S., we continue to actively enroll the CardiAMP Heart Failure II trial to take this study to completion as our confirmatory phase III study. Four clinical sites have enrolled in the study and are actively recruiting patients.
There have been no safety issues of which management is aware. The rate of enrollment here is driven primarily by resources deployed, and we are actively onboarding an additional seven world-class centers. We expect to have additional exciting news here. The second significant regulatory milestone in the near term is related to FDA's potential approval of our Helix Transendocardial Delivery Catheter System in the U.S. There is significant data on this delivery platform, with data from a dozen clinical trials with approximately 500 patients. In our last quarter, we shared we were waiting the FDA minutes from our May 2026 meeting. Soon after our Q2 earnings call in August, the FDA accepted as final the minutes that we had provided without changes. We have recently filed a supplemental De Novo pre-submission to the FDA, which has been accepted.
We expect to hear from the FDA on this pre-submission in the next six weeks. If the FDA supports the De Novo approval pathway for Helix, we expect to complete the De Novo submission in the first quarter of 2027, with approval in mid-2027 if FDA meets its official target goal of 150 review days under the Medical Device User Fee Amendments guidelines. If the FDA does not support the De Novo approval pathway, there will be additional discussions ahead. We firmly believe that there is every reason for the Helix to be approved and intend to work with the agency to make this happen.
In addition to the role of the investigational Helix platform for our own therapeutic development activities, Helix has potential to become the leading development platform for biologic therapies to treat heart disease, as it provides efficient delivery and control for these investigational agents to the heart. We have enhancements to Helix that will impact our investigational cardiac therapies as well as those of partners. This includes our FDA-cleared Morph DNA navigation platform and our investigational Heart3D Fusion Imaging platform. Our business development falls into two separate efforts primarily. The first is on the therapeutic front, driven by the interest in CardiAMP Cell Therapy. Conversations here of interest are around our cardiovascular portfolio.
A deal has potential to include our entire cardiovascular pipeline, including CardiAMP for its second indication of chronic myocardial ischemia and our allogeneic CardiALLO cell therapy for inflammatory heart failure, both of which are well-positioned with clinical data and a pathway to market clearance. BioCardia is fully committed to the post-marketing study launch in Japan with our expertise, but we do recognize the value that a partner has for long-term growth in Japan and the Asia-Pacific region. Business development on biotherapeutic delivery is also active. We believe we can help many of those in development, particularly for gene-based therapies. In the last 72 hours, we've had conversations on four separate gene therapy collaborations. Under confidentiality, we are helping partners appreciate what is possible with our delivery technologies. There is a great deal more possible with intramyocardial delivery that is not well appreciated by many firms today.
These possibilities are enhanced by the potential of Heart3D Fusion Imaging, which we are working diligently with our respected partner, CART-Tech, to bring to the clinic and to the market as soon as possible. I will now pass the call to David McClung, our CFO, who will review our third quarter 2026 financial results.
David? Thank you, Peter, and good afternoon, everyone.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
5 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
